Meiji Seika Pharma
Japanese pharmaceutical company focused on infectious disease therapeutics and vaccines, generic medicines, plasma-derived therapeutics, and related R&D. Maintains multi-site GMP manufacturing and global supply networks, conducts clinical development and pharmacovigilance, develops diagnostics and digital patient/HCP tools, and collaborates with external partners on vaccine and API production (including next-generation mRNA platforms and domestic API scale-up).
Industries
Nr. of Employees
Very Large (1000+)
Patents
Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
US-12617844-B2
View DetailsTherapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases
US-12239643-B2
View DetailsCrystalline forms of diazabicyclooctane derivative and production process thereof
US-12221443-B2
View Details
Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
US-12617844-B2
View DetailsTherapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases
US-12239643-B2
View DetailsCrystalline forms of diazabicyclooctane derivative and production process thereof
US-12221443-B2
View DetailsProducts
Next-generation mRNA/replicon vaccine for SARS-CoV-2
A replicon-type mRNA vaccine developed for COVID-19, advanced to regulatory approval and supplied in specified markets.
SARS-CoV-2 lateral-flow antigen test kit
Lateral-flow antigen diagnostic kit for qualitative detection of SARS-CoV-2 antigen with user instructions and multilingual materials.
Plasma-derived therapeutics (plasma fractionation products)
Plasma fractionation products manufactured from donor plasma for clinical use.
Generic pharmaceuticals portfolio
Manufacture and supply of generic medicines with quality assurance and information support for healthcare professionals.
Next-generation mRNA/replicon vaccine for SARS-CoV-2
A replicon-type mRNA vaccine developed for COVID-19, advanced to regulatory approval and supplied in specified markets.
SARS-CoV-2 lateral-flow antigen test kit
Lateral-flow antigen diagnostic kit for qualitative detection of SARS-CoV-2 antigen with user instructions and multilingual materials.
Plasma-derived therapeutics (plasma fractionation products)
Plasma fractionation products manufactured from donor plasma for clinical use.
Generic pharmaceuticals portfolio
Manufacture and supply of generic medicines with quality assurance and information support for healthcare professionals.
Services
Manufacturing services for oral jelly dosage forms on a contract basis.
Packaging services for injectable products, including packaging lines and quality controls.
Contract analytical testing and inspection services with documented equipment lists and testing capabilities.
Contract development and manufacturing services provided through group CMO/CDMO operations and overseas production sites to support global export and domestic supply.
Manufacturing services for oral jelly dosage forms on a contract basis.
Packaging services for injectable products, including packaging lines and quality controls.
Contract analytical testing and inspection services with documented equipment lists and testing capabilities.
Contract development and manufacturing services provided through group CMO/CDMO operations and overseas production sites to support global export and domestic supply.
Expertise Areas
- Vaccine development (including next-generation mRNA/replicon)
- Clinical trial management and regulatory reporting
- GMP-compliant multi-site manufacturing and CMO/CDMO operations
- API production and fermentation-based antibiotic manufacturing
Key Technologies
- Replicon/mRNA vaccine platforms
- Large-scale biologics and vaccine manufacturing
- Fermentation-based API production (antibiotics)
- Lateral-flow antigen immunoassays
News & Updates
Article describing regulatory approval and start of supply for a replicon-type mRNA vaccine for COVID-19 (reported approval and supply progression in site article).
Program to restart domestic production of penicillin raw material (6-APA) with target for full-scale manufacturing aimed at 2025 to improve supply stability.
Announcement of a partnership to build a stable supply system for penicillin raw material (API).
Introduction of a web-based tool to assist long-term follow-up after hematopoietic cell transplantation.
Completion of a raw-material manufacturing building at a partner site as part of establishing domestic mRNA production capability.
Article describing regulatory approval and start of supply for a replicon-type mRNA vaccine for COVID-19 (reported approval and supply progression in site article).
Program to restart domestic production of penicillin raw material (6-APA) with target for full-scale manufacturing aimed at 2025 to improve supply stability.
Announcement of a partnership to build a stable supply system for penicillin raw material (API).
Introduction of a web-based tool to assist long-term follow-up after hematopoietic cell transplantation.
Completion of a raw-material manufacturing building at a partner site as part of establishing domestic mRNA production capability.